c-erbB-2 oncogene as a prognostic marker in breast cancer.

por Perren, T. J.
Publicado 1991

Adjuvant therapy for operable breast cancer; more answers, new questions.

por Perren, T. J.
Publicado 1995

The Cytotoxics Handbook

por Perren, T.J.
Publicado 1991

Recent EORTC and MRC UK studies: implications for imaging ovarian cancer

por Spencer, John A., Perren, Timothy J.
Publicado 2010

Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease.

por Perren, T. J., Selby, P. J., Milan, S., Meldrum, M., McElwain, T. J.
Publicado 1990

Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.

por Lakhani, S., Selby, P., Bliss, J. M., Perren, T. J., Gore, M. E., McElwain, T. J.
Publicado 1990

Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies.

por Banks, R. E., Gearing, A. J., Hemingway, I. K., Norfolk, D. R., Perren, T. J., Selby, P. J.
Publicado 1993

High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.

por Zulian, G. B., Selby, P., Milan, S., Nandi, A., Gore, M., Forgeson, G., Perren, T. J., McElwain, T. J.
Publicado 1989

Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire b...

por Humphreys, A C, Dent, J, Rodwell, S, Crawford, S M, Joffe, J K, Bradley, C, Dodwell, D, Perren, T J
Publicado 2004

The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer.

por Ward, U., Primrose, J. N., Finan, P. J., Perren, T. J., Selby, P., Purves, D. A., Cooper, E. H.
Publicado 1993

A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma.

por Joffe, J. K., Perren, T. J., Bradley, C., Primrose, J., Hallam, S., Ward, U., Illingworth, J. M., Selby, P. J.
Publicado 1997

Timing of breast cancer surgery in relation to menstrual cycle phase: no effect on 3-year prognosis: The ITS Study

por Thorpe, H, Brown, S R, Sainsbury, J R, Perren, T J, Hiley, V, Dowsett, M, Nejim, A, Brown, J M
Publicado 2008

Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation

por Dent, J, Hall, G D, Wilkinson, N, Perren, T J, Richmond, I, Markham, A F, Murphy, H, Bell, S M
Publicado 2003

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.

por Perren, T. J., Wiltshaw, E., Harper, P., Slevin, M., Stein, R., Tan, S., Gore, M., Fryatt, I. J., Blake, P. R.
Publicado 1993

Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7)

por Colomban, Olivier, Tod, Michel, Peron, Julien, Perren, Timothy J, Leary, Alexandra, Cook, Adrian D, Sajous, Christophe, Freyer, Gilles, You, Benoit
Publicado 2020

The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation.

por Selby, P. J., Powles, R. L., Easton, D., Perren, T. J., Stolle, K., Jameson, B., Fiddian, A. P., Tryhorn, Y., Stern, H.
Publicado 1989

High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.

por Mbidde, E. K., Selby, P. J., Perren, T. J., Dearnaley, D. P., Whitton, A., Ashley, S., Workman, P., Bloom, H. J., McElwain, T. J.
Publicado 1988

Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study

por Hall, G D, Brown, J M, Coleman, R E, Stead, M, Metcalf, K S, Peel, K R, Poole, C, Crawford, M, Hancock, B, Selby, P J, Perren, T J
Publicado 2004

Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?

por Cameron, D A, Anderson, A, Toy, E, Evans, T R J, Le Vay, J H, Kennedy, I C S, Grieve, R J, Perren, T J, Jones, A, Mansi, J, Crown, J, Leonard, R C F
Publicado 2002

Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response

por Stevens, William, Farrow, Isabelle M, Georgiou, Leonidas, Hanby, Andrew M, Perren, Timothy J, Windel, Laura M, Wilson, Daniel J, Sharma, Nisha, Dodwell, David, Hughes, Thomas A, Dall, Barbara JG, Buckley, David L
Publicado 2021